Simulations Plus — stock news & what’s moving it

All Simulations Plus news

• HSR antitrust waiting period expires for merger with SP EvolutionAug 13, 2026 · This removes a key regulatory hurdle for Simulations Plus's merger, signaling progress towards the acquisition by SP Evo
• Simulations Plus Q3 revenue up 7% to $21.9M; services revenue up 20%; net income $3.6MJul 9, 2026 · The strong growth in services revenue indicates robust demand for specialized drug development solutions, while the flat
• Simulations Plus advances drug development with NVIDIA BioNeMo Agent ToolkitJun 23, 2026 · Simulations Plus Advances Agentic Drug Development with NVIDIA BioNeMo Agent Toolkit Yahoo Finance